BPC-157
A synthetic 15-residue peptide derived from a partial sequence of human gastric juice protein. BPC-157 has been studied for over two decades by the Sikiric group in Zagreb, with a literature dominated by animal models of tendon outgrowth, intestinal mucosa repair, and vascular response.1
BPC-157 has the longest research record of any “investigational” peptide,with consistent observation across rodent and rabbit models that healing of tendon, ligament, intestinal mucosa, and vessel proceeds at higher rate and quality than vehicle controls. The peptide's stability in gastric juice — survival of oral administration with measurable bioactivity — is mechanistically unusual and clinically interesting.1
The literature is, however, geographically concentrated. Most studies originate from a single Croatian research group; independent replication in randomised, blinded human trials has not yet been published in indexed journals. We classify the protocol asinvestigational: mechanistically plausible, animal-supported, and human-untested at trial level.
Where the report flags BPC-157 as a candidate, it is for a biomarker-supported indication — elevated hsCRP in the context of training load, or postsurgical recovery with adequate ferritin and baseline metabolic markers — not as a general “anti-aging” stack component.
and growth-factor cross-talk.
Proposed mechanisms include upregulation of growth-hormone receptor on tendon fibroblasts2, modulation of the L-arginine / NO system, and promotion of angiogenic response via VEGF signaling. The peptide appears to accelerate the rate of granulation and remodeling phases of repair rather than altering the initial inflammatory phase.4
Tendinopathy
Tendon outgrowth, cell survival, migration. Animal data dominate; case-series in athletes circulate without published trial.2
Ligament injury
Achilles transection model in rat: accelerated functional recovery vs. vehicle.3
GI mucosa
Original indication line. Studied in DSS colitis, NSAID gastropathy, esophageal injury models.1
Vascular
Vessel-running phenomenon observed in occlusion models; mechanism via VEGF / NO axis.4
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.
Foundational review of GI applications. Discusses oral bioavailability hypothesis and mucosa-protective effects across NSAID and ulcer models.
21548867
Promoting effect of BPC 157 on tendon healing: outgrowth, survival, migration.
In-vitro tendon-fibroblast and rat patellar tendon transection study. Reports accelerated functional recovery and altered GH-receptor expression.
21030672
Achilles detachment in rat and stable gastric pentadecapeptide BPC 157.
Rat Achilles detachment-reattachment model. BPC-157 treated animals returned to weight bearing earlier with histologic markers of tendon-to-bone integration.
16583453
BPC 157 and blood vessels.
Review of the “vessel-running” phenomenon. Synthesis of occlusion models and proposed VEGF / NO mechanism.
23782145
and the explicit safety caveats.
| Indication | Dose | Schedule | Duration |
|---|---|---|---|
| Tendinopathy | 250 µg SC | BID, periarticular | 4–6 wk |
| GI mucosa | 200–500 µg PO | Daily, fasting | 2–4 wk |
| General recovery | 200 µg SC | Daily, AM | 4 wk |
Monitoring. Track the indication-specific symptom inventory at baseline, week 2, and week 4. Re-test hsCRP and ferritin at week 4 if used for systemic inflammation. Hold the protocol if hsCRP rises ≥ 50% from baseline.